Antiamoebic properties of the actinomycete metabolites echinomycin A and tirandamycin A

作者：Espinosa Avelina^*; Socha Aaron M; Ryke Erica; Rowley David C

来源：Parasitology Research, 2012, 111(6): 2473-2477.

DOI：10.1007/s00436-012-3019-2

Entamoeba histolytica infects 50 million people per year, causing 100,000 deaths worldwide. The primary treatment for amoebiasis is metronidazole. However, increased pathogen resistance combined with the drug%26apos;s toxic side effects encourages a search for alternative therapeutic agents. Secondary metabolites from marine bacteria are a promising resource for antiprotozoan drug discovery. In this study, extracts from a collection of marine-derived actinomycetes were screened for antiamoebic properties, and the activities of antibiotics echinomycin A and tirandamycin A are shown. Both antibiotics inhibited the in vitro growth of a E. histolytica laboratory strain (HM-1:IMSS) and a clinical isolate (Colombia, Col) at 30- to 60-mu M concentrations. EIC50 (estimated inhibitory concentration) values were comparable for both antibiotics (44.3-46.3 mu M) against the E. histolytica clinical isolate.

• 出版日期2012-12